NCT03489239View on ClinicalTrials.gov

Entecavir to TAF Switch

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

August 15, 2020

Study Completion Date

September 16, 2020

Conditions

Hepatitis B

Interventions

DRUG

Tenofovir Alafenamide

subjects switching from Entecavir to single arm TAF 25mg

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Thomas Jefferson University

OTHER